Pharvaris (NASDAQ:PHVS – Get an assessment) had its target price lowered by research analysts SVB Leerink from $25.00 to $20.00 in a research note released on Wednesday, Stock Target Advisor reports. The brokerage currently has an “outperform” rating on the stock. SVB Leerink’s price target indicates a potential upside of 120.51% from the company’s current price.
PHVS has been the subject of several other reports. Oppenheimer lowered his price target on Pharvaris shares from $48.00 to $22.00 and set an “outperform” rating on the stock in a Tuesday, August 23 research report. Morgan Stanley downgraded shares of Pharvaris from an “overweight” rating to an “equal weight” rating and lowered its target price for the company from $40.00 to $10.00 in a Tuesday, August 23 research report . Bank of America downgraded Pharvaris shares from a “neutral” to an “underperforming” rating and lowered its target price for the company from $26.00 to $13.00 in a Monday research report August 22. Finally, JMP Securities lowered its price target on Pharvaris shares from $34.00 to $18.00 and set an “outperform mkt” rating on the stock in a research report on Tuesday. One analyst rated the stock with a sell rating, another assigned a hold rating and two assigned the stock a buy rating. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $16.60.
Phavaris Price Performance
The NASDAQ PHVS opened at $9.07 on Wednesday. The company has a market capitalization of $288.79 million, a price-earnings ratio of -3.49 and a beta of -0.19. The company’s fifty-day moving average is $17.03 and its two-hundred-day moving average is $18.05. Pharvaris has a 52-week minimum of $8.55 and a 52-week maximum of $27.50.
Pharvaris (NASDAQ:PHVS – Get Rating) last released its quarterly results on Monday, September 12. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.19. As a group, sell-side analysts expect Pharvaris to post earnings per share of -2.18 for the current fiscal year.
Hedge funds weigh on Pharvaris
Institutional investors have recently increased or reduced their stake in the company. Suvretta Capital Management LLC bought a new position in shares of Pharvaris in the fourth quarter worth approximately $11,908,000. Novo Holdings AS increased its stake in Pharvaris shares by 23.2% in the fourth quarter. Novo Holdings AS now owns 516,321 shares of the company worth $7,430,000 after acquiring an additional 97,378 shares in the last quarter. Eventide Asset Management LLC increased its stake in Pharvaris shares by 23.6% in the first quarter. Eventide Asset Management LLC now owns 302,619 shares of the company worth $5,659,000 after acquiring an additional 57,694 shares in the last quarter. Viking Global Investors LP increased its stake in Pharvaris shares by 1.0% in the first quarter. Viking Global Investors LP now owns 2,480,319 shares of the company worth $46,382,000 after acquiring 24,783 additional shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Pharvaris shares by 1,054.4% in the first quarter. Bank of America Corp DE now owns 5,772 shares of the company worth $105,000 after acquiring 5,272 additional shares in the last quarter. 70.21% of the shares are held by institutional investors.
Phavaris Company Profile
(Get a rating)
Pharvaris NV, a clinical-stage biopharmaceutical company, is focused on developing and commercializing therapies for rare diseases. The company is developing PHA121, a small molecule bradykinin B2 receptor antagonist that is in a phase II clinical trial for the treatment of hereditary angioedema (HAE).
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to email@example.com.
Before you consider Pharvaris, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Pharvaris didn’t make the list.
Although Pharvaris currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here